Committee sends proposed insurance mandate for continuous glucose monitors to interim study after cost and mandate debate

The House Commerce and Consumer Affairs committee discussed House Bill 648, which would expand insurance coverage for continuous glucose monitoring devices. Representative Miles (a nurse) said she is sympathetic to the medical benefits of CGMs but moved to declare the bill inexpedient to legislate, arguing that insurers already cover CGMs when clinically appropriate and that a new state mandate would increase premiums. After additional debate and a brief procedural withdrawal of the ITL motion, Representative Spear moved and the committee approved sending the bill to interim study.

Members debated whether a state mandate would trigger the Affordable Care Act requirement that new state insurance mandates be state‑funded for people in individual market plans. One committee member said the insurance department provided a 20‑page fiscal report and estimated an approximate $10 per‑person impact; others disputed whether cost could be estimated robustly in committee and said costs were uncertain. Committee members also discussed limiting any coverage expansion to a physician prescription or clinical necessity rather than an unconditional entitlement.

Representative Miles withdrew her original ITL motion; the committee then passed a motion for interim study on a roll call of 11–6. The interim study disposition leaves the bill on the committee’s calendar for further consideration and gives members time to review fiscal data and refine language, including prescription or clinical-necessity limits discussed in committee.

No final mandate or funding mechanism was adopted; the committee’s action means sponsors and staff must provide additional fiscal and drafting information for future consideration.